New Data on Crenezumab and Gantenerumab
At the upcoming American Academy of Neurology (AAN) meeting beginning on April 21st, 2018, new data on investigational monoclonal antibodies against amyloid-ß (Aß) crenezumab and gantenerumab, (Genentech, San Francisco, CA), will be presented. Both antibodies are promising for the treatment of Alzheimer’s disease, and have informed the design for 2 phase 3 clinical trial programs.
Data from 2 open-label extension studies showing that there is a significant reduction in brain amyloid-ß plaques after treatment with a high-dose (1200 mg) regimen of gantenerumab. Data from these studies guided the dose and titration regimen selection for the recently initiated phase 3 GRADUATE pivotal investigation of gantenerumab for the treatment of early Alzheimer’s disease.
Preclinical data for crenezumab will be presented regarding proposed mechanism of action and preferential binding of crenezumab to neurotoxic Aß oligomers. Results from a safety, tolerability, and pharmacokinetics phase 1b study of doses up to 120 mg will also be presented. The latter has been used to determine an optimal dose for the ongoing CREAD pivotal program investigating crenezumab for the treatment of early Alzheimer’s disease.
Visit us at www.practicalneurology.com to see more news of these and other results from the AAN meeting!